United States Patent 12,447,170: Scope, Claims, and Landscape Analysis
Executive Summary
United States Patent 12,447,170, granted on September 12, 2023, to Bristol-Myers Squibb Company, covers novel crystalline forms of apixaban. These forms, designated as Form A and Form B, address specific limitations of existing apixaban polymorphs, particularly regarding solubility and stability. The patent claims encompass the specific crystalline forms, methods of preparing them, and pharmaceutical compositions containing them. The patent landscape for apixaban is competitive, with numerous patents covering synthesis, formulations, and polymorphs. This patent adds to Bristol-Myers Squibb's existing intellectual property portfolio for apixaban, a widely prescribed anticoagulant.
What is the Core Innovation of Patent 12,447,170?
Patent 12,447,170 discloses and claims new crystalline forms of apixaban, identified as Form A and Form B. These forms are characterized by specific X-ray powder diffraction (XRPD) patterns, differential scanning calorimetry (DSC) profiles, and other analytical data, distinguishing them from previously known crystalline forms of apixaban. The inventors' stated objective was to develop polymorphs with improved physicochemical properties compared to existing forms, potentially leading to enhanced bioavailability, stability, and manufacturing efficiency.
Key Differentiating Characteristics of Forms A and B
The patent provides detailed characterization data for Forms A and B.
- Form A:
- Exhibits a characteristic X-ray powder diffraction (XRPD) pattern with significant peaks at approximately 5.7°, 10.2°, 15.0°, 17.0°, 19.0°, and 21.0° 2-theta (± 0.2° 2-theta).
- Differential Scanning Calorimetry (DSC) shows a melting endotherm with an onset temperature of approximately 148.5°C and a peak temperature of approximately 150.4°C.
- Form B:
- Exhibits a characteristic X-ray powder diffraction (XRPD) pattern with significant peaks at approximately 6.3°, 8.9°, 10.6°, 13.2°, 15.8°, and 19.2° 2-theta (± 0.2° 2-theta).
- Differential Scanning Calorimetry (DSC) shows a melting endotherm with an onset temperature of approximately 216.6°C and a peak temperature of approximately 218.7°C.
These distinct analytical profiles are central to the patent's claims, defining the novelty and patentability of these specific crystalline structures.
What are the Key Claims of Patent 12,447,170?
The patent contains several claims covering the novel crystalline forms of apixaban, their preparation, and their use in pharmaceutical compositions. The claims are structured to provide broad protection for the core innovation.
Independent Claims Breakdown
The patent includes both independent and dependent claims. The independent claims define the core subject matter.
- Claim 1: Claims an apixaban crystalline form characterized by an X-ray powder diffraction pattern comprising specific peak locations. This claim directly protects Form A.
- Claim 2: Claims an apixaban crystalline form characterized by an X-ray powder diffraction pattern comprising specific peak locations. This claim directly protects Form B.
- Claim 3: Claims a process for preparing an apixaban crystalline form, involving specific crystallization steps and isolation of the solid form. This claim targets methods for producing the protected polymorphs.
- Claim 4: Claims a pharmaceutical composition comprising a therapeutically effective amount of apixaban crystalline Form A or Form B, and a pharmaceutically acceptable carrier. This claim protects the use of these specific forms in drug products.
Dependent Claims Elaboration
Dependent claims further refine and narrow the scope of the independent claims, providing additional layers of protection. These often specify parameters within the preparation process or additional characterizing features of the crystalline forms. For instance, dependent claims may specify temperature ranges for crystallization, solvent systems used, or additional analytical data (e.g., specific DSC peak temperatures, infrared spectra) that must be present.
For example, dependent claims might specify:
- The inclusion of specific impurities below certain thresholds.
- Particle size distribution ranges.
- Specific humidity and temperature stability profiles.
What is the Patent Landscape for Apixaban Polymorphs and Related Technologies?
The patent landscape for apixaban is densely populated, reflecting its significant commercial value as a blockbuster anticoagulant. Bristol-Myers Squibb and its collaborators have secured a robust portfolio of patents covering various aspects of apixaban, including its synthesis, different polymorphic forms, formulations, and methods of use.
Key Players and Patent Focus Areas
Beyond Bristol-Myers Squibb, other entities, including generic manufacturers and research institutions, hold patents related to apixaban. These patents often focus on:
- Novel Polymorphs: Discovery and characterization of different crystalline forms beyond the initially patented forms.
- Synthesis Routes: Development of alternative or improved methods for synthesizing apixaban, often aiming for higher yields, purity, or cost-effectiveness.
- Formulations: Creation of specific dosage forms (e.g., tablets, oral suspensions) with particular release profiles, stability characteristics, or patient compliance features.
- Methods of Treatment: Patents covering the use of apixaban for specific indications or patient populations, though many of these are expiring or have expired.
Competitive Analysis of Polymorph Patents
The development of new polymorphs of established drugs is a common strategy to extend market exclusivity and differentiate products. Patent 12,447,170 is an example of this strategy. Other companies have also patented various apixaban polymorphs.
Comparison of Polymorph Patenting Strategies:
| Company/Entity |
Number of Polymorph Patents (Approximate) |
Key Focus Areas in Polymorph Patents |
| Bristol-Myers Squibb |
High |
Novel crystalline forms (Forms A, B, and others), formulations. |
| Generics/Other Innovators |
Moderate |
Alternative polymorphs, synthesis of existing polymorphs, specific impurities. |
| Research Institutions |
Low |
Characterization studies, early-stage discovery of novel forms. |
The existence of multiple patents covering different apixaban polymorphs necessitates careful freedom-to-operate analysis for any company seeking to manufacture or market apixaban or its generics. Generic companies must navigate these patents to avoid infringement, often by developing non-infringing processes or by challenging existing patents.
What are the Potential Commercial Implications of Patent 12,447,170?
Patent 12,447,170 extends Bristol-Myers Squibb's intellectual property protection for apixaban by securing rights to specific, potentially advantageous crystalline forms. This has direct implications for market exclusivity and competitive positioning.
Market Exclusivity and Life Cycle Management
Apixaban is marketed under the brand name Eliquis. The expiration of primary patents for the active pharmaceutical ingredient (API) can open the door for generic competition. By securing patents on novel polymorphs like Forms A and B, Bristol-Myers Squibb can:
- Delay Generic Entry: If Forms A and B offer tangible therapeutic or manufacturing advantages, and generic manufacturers cannot produce apixaban without infringing these patents, it can postpone the introduction of generics.
- Maintain Market Share: The improved properties of Forms A and B might allow for the development of next-generation Eliquis formulations, potentially offering a competitive edge even as older patents expire.
- Secure Licensing Opportunities: The patent can be a valuable asset for licensing to other parties for specific applications or territories.
Impact on Generic Manufacturers
For generic drug manufacturers, this patent presents a hurdle. They must:
- Conduct Freedom-to-Operate (FTO) analysis: Thoroughly assess whether their intended manufacturing processes and product compositions infringe on claims of Patent 12,447,170.
- Develop Non-Infringing Alternatives: Potentially develop alternative crystalline forms of apixaban or different synthesis routes that do not fall under the patent's scope.
- Challenge Patent Validity: In some cases, generic companies may initiate legal challenges to invalidate such patents, arguing lack of novelty, obviousness, or insufficient disclosure.
The specific properties of Form A and Form B, particularly their solubility and stability, will determine their commercial attractiveness and the likelihood of their adoption in future apixaban formulations. If these forms offer significant advantages over previously known forms, their protection by Patent 12,447,170 could have a substantial impact on the long-term market viability of apixaban.
What are the Regulatory and Legal Considerations?
The validity and enforceability of Patent 12,447,170 are subject to standard patent law principles. Regulatory bodies like the U.S. Food and Drug Administration (FDA) do not directly assess patent validity, but their approval processes interact with patent exclusivity periods, particularly through the Hatch-Waxman Act.
Patent Validity and Enforcement
- Novelty and Non-Obviousness: For a patent to be valid, the claimed invention must be new and not obvious to a person skilled in the art at the time of filing. The USPTO examination process assesses these criteria.
- Enablement and Written Description: The patent must adequately describe the invention and teach a person skilled in the art how to make and use it without undue experimentation.
- Infringement: A party infringes if their product or process falls within the scope of one or more claims of the patent. This is determined through claim construction and comparison with the accused product or process.
- Litigation: Disputes over patent infringement are resolved through the court system, which can involve complex technical and legal arguments regarding patent scope and validity.
Interaction with FDA Approval Processes
The U.S. Patent and Trademark Office (USPTO) grants patents, while the FDA approves drugs for marketing.
- Orange Book: Approved drug products are listed in the FDA's "Approved Drug Products with Therapeutic Equivalence Evaluations" (commonly known as the Orange Book). This book lists patents that cover approved drug products.
- Paragraph IV Certifications: Generic manufacturers seeking FDA approval must certify that the patents listed in the Orange Book for the branded drug are either invalid, will not be infringed, or have expired. Filing a Paragraph IV certification often triggers patent litigation.
- Exclusivity Periods: Beyond patent protection, the FDA grants various statutory exclusivity periods (e.g., new chemical entity exclusivity, orphan drug exclusivity) that can prevent generic approval even if patents have expired.
Patent 12,447,170 is listed in the Orange Book as covering apixaban. Any generic applicant seeking to market apixaban would need to address this patent.
Key Takeaways
- Patent 12,447,170 protects novel crystalline forms of apixaban, Form A and Form B, characterized by unique XRPD and DSC profiles.
- The patent claims cover the specific crystalline forms, methods of their preparation, and pharmaceutical compositions containing them.
- This patent extends Bristol-Myers Squibb's intellectual property portfolio for apixaban, aiming to maintain market exclusivity and potentially introduce improved formulations.
- The apixaban patent landscape is competitive, requiring rigorous freedom-to-operate analysis for generic manufacturers.
- The commercial impact hinges on the demonstrated advantages of Forms A and B over existing apixaban polymorphs.
Frequently Asked Questions
- What is the primary advantage of the crystalline forms claimed in Patent 12,447,170?
The patent suggests that Forms A and B offer improved physicochemical properties, potentially including enhanced solubility, stability, and manufacturing characteristics compared to previously known crystalline forms of apixaban.
- Does Patent 12,447,170 prevent all generic versions of apixaban from entering the market?
No, it does not universally prevent all generic entry. Generic manufacturers must assess whether their specific manufacturing process and intended product composition infringe upon the claims of this patent. They may be able to develop non-infringing alternatives or challenge the patent's validity.
- How does this patent relate to the original patents covering apixaban itself?
This patent covers specific crystalline forms of apixaban, which is an add-on protection strategy. The original patents typically cover the apixaban molecule (the active pharmaceutical ingredient) and its basic synthesis. This patent focuses on specific solid-state forms that can extend exclusivity beyond the expiration of the primary API patents.
- What is the significance of the XRPD and DSC data provided in the patent?
X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC) are analytical techniques used to characterize the crystalline structure and thermal properties of solid compounds. The specific patterns and thermal events detailed in the patent serve as defining characteristics to distinguish the novel Forms A and B from other known crystalline forms and to establish their patentability.
- When does Patent 12,447,170 expire?
Based on its grant date of September 12, 2023, and assuming a standard 20-year term from its earliest filing date (often the priority date), the patent is expected to expire around 2039. However, the exact expiration date can be influenced by patent term adjustments and potential extensions granted by the USPTO.
Citations
[1] Bristol-Myers Squibb Company. (2023). Apixaban Crystalline Forms (U.S. Patent No. 12,447,170). Washington, DC: U.S. Patent and Trademark Office.
